Bayer AG annual r&d spending
2021
2022
2023
2024
2025
Bayer AG R&D Spending Growth & History (BAYN)
Bayer AG's r&d spending was €5.77B for fiscal 2025.
View full Bayer AG company overviewBayer AG annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €5.77B | −€440.0M | −7.09% |
| 2024 | 2024-12-31 | €6.21B | €838.0M | +15.60% |
| 2023 | 2023-12-31 | €5.37B | −€1.20B | −18.27% |
| 2022 | 2022-12-31 | €6.57B | €1.16B | +21.43% |
| 2021 | 2021-12-31 | €5.41B | — | — |
Bayer AG quarterly r&d spending
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €1.52B | €110.0M | +7.81% |
| Q1 2026 | 2026-03-31 | €1.42B | — | — |
| Q4 2025 | 2025-12-31 | €1.41B | — | — |
| Q3 2025 | 2025-09-30 | €1.50B | — | — |
| Q2 2025 | 2025-06-30 | €1.41B | — | — |
Bayer AG r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Bayer AG's r&d spending increased from €5.41B to €5.77B, a change of €357.0M. The latest reported quarter, Q2 2026, shows €1.52B.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
reported R&D expense
TickerStat standardizes research and development expense reported in company official filings, including the software-specific standardized R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
